Literature DB >> 31466831

Management of colorectal peritoneal metastases: Expert opinion.

K Abboud1, T André2, M Brunel3, M Ducreux4, C Eveno5, O Glehen6, D Goéré7, J-M Gornet8, J H Lefevre9, P Mariani10, A Pinto11, F Quenet12, O Sgarbura12, M Ychou13, M Pocard14.   

Abstract

When peritoneal metastases are diagnosed (strong agreement of experts): (i) seek advice from a multidisciplinary coordination meeting (MCM) with large experience in peritoneal disease (e.g. BIG RENAPE network); (ii) transfer (or not) the patient to a referral center with experience in hyperthermic intraperitoneal chemotherapy (HIPEC), according to the advice of the MCM. With regard to systemic chemotherapy (strong agreement of experts): (i) it should be performed both before and after surgery, (ii) for no longer than 6 months; (iii) without postoperative anti-angiogenetic drugs. With regard to cytoreductive surgery (strong agreement of experts): (i) Radical surgery requires a xiphopubic midline incision; (ii) no cytoreductive surgery via laparoscopy. With regard to HIPEC: HIPEC can be proposed for trials outside an HIPEC referral center (weak agreement between experts): (i) if surgery is radical; (ii) if the expected morbidity is "reasonable"; (iii) if the indication for HIPEC was suggested by a MCM, and; (iv) mitomycin is preferred to oxaliplatin (which cannot be recommended) for this indication.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Carcinomatosis; Colon cancer; Cytoreductive surgery; HIPEC

Year:  2019        PMID: 31466831     DOI: 10.1016/j.jviscsurg.2019.08.002

Source DB:  PubMed          Journal:  J Visc Surg        ISSN: 1878-7886            Impact factor:   2.043


  10 in total

1.  Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Alfonso García-Fadrique; Rafael Estevan Estevan; Luis Sabater Ortí
Journal:  Ann Surg Oncol       Date:  2021-08-25       Impact factor: 5.344

Review 2.  Primary and metastatic peritoneal surface malignancies.

Authors:  Delia Cortés-Guiral; Martin Hübner; Mohammad Alyami; Aditi Bhatt; Wim Ceelen; Olivier Glehen; Florian Lordick; Robert Ramsay; Olivia Sgarbura; Kurt Van Der Speeten; Kiran K Turaga; Manish Chand
Journal:  Nat Rev Dis Primers       Date:  2021-12-16       Impact factor: 52.329

3.  Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.

Authors:  Abdelkader Taibi; Olivia Sgarbura; Martin Hübner; Sylvia M Bardet; Mohammed Alyami; Naoual Bakrin; Sylvaine Durand Fontanier; Clarisse Eveno; Johan Gagniere; Basile Pache; Marc Pocard; François Quenet; Hugo Teixeira Farinha; Emilie Thibaudeau; Frederic Dumont; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2022-03-22       Impact factor: 4.339

4.  GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases.

Authors:  Fernando Pereira; Angel Serrano; Israel Manzanedo; Estibalitz Pérez-Viejo; Santiago González-Moreno; Luis González-Bayón; Alvaro Arjona-Sánchez; Juan Torres; Isabel Ramos; Maria E Barrios; Pedro Cascales; Rafael Morales; Enrique Boldó; Alfonso García-Fadrique; Xabier Arteaga; Alberto Gutierrez-Calvo; Susana Sánchez-García; Enrique Asensio; Cesar P Ramírez; Manuel Artiles; Javier Vaqué; Pedro A Parra; Pedro Villarejo; Cristóbal Muñoz-Casares; Estrella Turienzo; Alicia Calero; Isabel Jaén Torrejimeno; Isabel Prieto; Julio Galindo; Vicente Borrego; Manuel E Marcello; Cristina Rihuete; Joaquin Carrasco; Luis Gomez-Quiles
Journal:  BMC Cancer       Date:  2022-05-12       Impact factor: 4.638

Review 5.  The Landmark Series: Surgical Treatment of Colorectal Cancer Peritoneal Metastases.

Authors:  Lana Bijelic; Isabel Ramos; Diane Goeré
Journal:  Ann Surg Oncol       Date:  2021-05-09       Impact factor: 5.344

6.  Results of systematic second-look surgery plus hipec in perforated or pt4 colon cancer. Case series.

Authors:  Ángel Serrano Del Moral; Estíbalitz Pérez Viejo; Israel Manzanedo Romero; Fernando Pereira Pérez
Journal:  Ann Med Surg (Lond)       Date:  2021-01-24

Review 7.  Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept.

Authors:  Christophe Bounaix Morand du Puch; Mathieu Vanderstraete; Stéphanie Giraud; Christophe Lautrette; Niki Christou; Muriel Mathonnet
Journal:  Theranostics       Date:  2021-09-21       Impact factor: 11.556

8.  10 ns PEFs induce a histological response linked to cell death and cytotoxic T-lymphocytes in an immunocompetent mouse model of peritoneal metastasis.

Authors:  A Taibi; M-L Perrin; J Albouys; J Jacques; C Yardin; S Durand-Fontanier; S M Bardet
Journal:  Clin Transl Oncol       Date:  2021-03-07       Impact factor: 3.405

9.  Study of oxaliplatin penetration into ovaries of patients treated with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases of colorectal and appendiceal origin using mass spectrometry imaging.

Authors:  Marion Larroque; Sandra Mounicou; Olivia Sgarbura; Carine Arnaudguilhem; Lucie Rebel; Cristina Leaha; Pierre-Arnaud Faye; Christine Enjalbal; François Quénet; Brice Bouyssiere; Sébastien Carrere
Journal:  Pleura Peritoneum       Date:  2021-03-24

10.  A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy After Oncological Resection of Pancreatic Adenocarcinoma.

Authors:  Can Yurttas; Philipp Horvath; Imma Fischer; Christoph Meisner; Silvio Nadalin; Ingmar Königsrainer; Alfred Königsrainer; Stefan Beckert; Markus W Löffler
Journal:  Ann Surg Oncol       Date:  2021-06-15       Impact factor: 5.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.